Company Overview and News

to your dashboard

Headline News

Gene Therapy Drugs: How To Avoid A Price Battle - Bloomberg

2017-11-17 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (28-1)

$1 million price tag in spotlight as gene therapy becomes reality

2017-11-16 reuters
LONDON (Reuters) - Battle lines are being drawn as the first gene therapy for an inherited condition nears the U.S. market, offering hope for people with a rare form of blindness and creating a cost dilemma for healthcare providers. (14-1)

Puma Biotechnology Faces Balance Sheet Anxiety

2017-11-10 seekingalpha
This loss will likely drive sell side analysts to push back expectations for break-even EBITDA to 2020 from 2019. (52-2)

Spark Therapeutics' (ONCE) CEO Jeff Marrazzo on Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Good day, ladies and gentlemen and welcome to the Third Quarter 2017 Spark Therapeutics Earnings Conference Call. At this time, all participants are in a listen-only mode and later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] (2-1)

36 Stocks For November 2017

2017-11-06 seekingalpha
Every month, we construct a theoretical long/short portfolio of stocks that demonstrates solid relative value with potential for ongoing cash flow growth and ROIC expansion. (703-1)

Nightstar Therapeutics: Gene Therapy Play

2017-11-01 seekingalpha
Lead clinical candidate NSR-REP1 is being evaluated for treating choroideremia with a pivotal program planned for 2018. (7-0)

Pfizer (PFE) Q3 2017 Results - Earnings Call Transcript

2017-10-31 seekingalpha
Good day, everyone, and welcome to Pfizer's Third Quarter 2017 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Please go ahead, sir. (80-0)

Your Daily Pharma Scoop: Soliris New Indication, Gilead's NASH Data, What Keeps Synergy Down?

2017-10-25 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service. (546-3)

Biotech Forum Daily Digest: Behind UniQure's Massive Rally

2017-10-23 seekingalpha
Sentiment on the biotech sector continues to be somewhat negative especially in the small cap part of this high beta part of the market. (210-1)

Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug

2017-10-18 zacks
With biotech sector earnings season round the corner, there were not too many updates this week. Important news this week include priority review for Exelixis’s (EXEL - Free Report) label expansion plans for Cabometyx and a positive FDA panel outcome for Spark Therapeutics’s (ONCE - Free Report) Luxturna. Recap of the Week’s Most Important Stories Exelixis Up on Priority Review from FDA: Exelixis’s shares shot up 17. (110-0)

Spark Therapeutics Ignites Excitement Over Unanimous Adcom Panel Vote

2017-10-17 seekingalpha
Advisory panel recommends unanimously with a 16 -0 vote that Luxturna should be approved by the FDA. (2-0)

Your Daily Pharma Scoop: ACRX Second Chance, AERI Rhopressa Success, Aratana ENTYCE Launch

2017-10-16 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (396-2)

Nightstar Therapeutics - Novel Gene Therapy Company And Recent IPO

2017-10-16 seekingalpha
The 2018 data release in X-linked retinitis pigmentosa indication is the next catalyst for the stock price. (81-0)

ICYMI: Lyft tops 500 million; McDonald’s Szechuan sauce shortage

2017-10-13 sfgate
•Lyft passed the 500 million-ride mark. No, not all of them were this week, though that would explain San Francisco traffic. The 5-year-old company said in a blog post that it has had 100 million rides in just the past three months. (2-0)

CUSIP: 84652J103